The progressive nature of Type 2 diabetes presents a challenge over the choice and course of treatment. Strict metabolic control is recommended to reduce the risk of diabetic morbidity and premature mortality. Treatment usually occurs in a step-wise manner as the insulin secretory capacity of the beta-cells diminishes. There are a variety of oral hypoglycaemic agents (OHAs) to choose from but the efficacy of all is influenced by beta-cell function. Eventual progression to insulin therapy is inevitable after beta-cell failure and it is important that this is not delayed. Insulin in combination with OHAs can significantly improve glycaemic control and provide a 'bridge' from oral-only to insulin-only therapy. Combination therapy requires few injections and there is a reduced tendency for weight gain compared with multiple insulin injection regimens. After starting insulin, metabolic control may significantly improve in OHA-treated patients. It is therefore prudent to initiate insulin at an early stage in the course of Type 2 diabetes. In this context, the use of premixed insulin analogues in combination with OHAs allows effective postprandial glucose control, a twice-daily injection regimen and a short meal-injection interval.
Introduction
Type 2 diabetes mellitus is a progressive disease, with high risk of cardiovascular and other complications. The progressive nature of the primary disease is evident from data collected from the Belfast Diet Study:
1 beta-cell function declined over time from diagnosis while insulin sensitivity remained relatively unchanged. Data from the UK Prospective Diabetes Study (UKPDS) also demonstrated a progressive deterioration in beta-cell function over 10 y. 2 Continuing loss of beta-cell function is associated with continuing rise in fasting plasma glucose (FPG) levels, both of which are significantly correlated with the duration of the disease.
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This evolution was apparent in UKPDS from the gradual increase in HbA 1c and FPG levels over the course of the study.
Major studies have demonstrated the association between poor glycaemic control and the development and progression of macrovascular and microvascular complications in both Type 1 and Type 2 diabetes. 2,4 -6 It has been shown that strict metabolic control (generally with insulin-based regimens) reduces the risk of diabetic morbidity, and importantly, that there is no threshold for improving HbA 1c % levels and risk reduction. 6 -8 Therefore, treatment is aimed at achieving the best possible glycaemic control for each patient. European and US guidelines recommend 'ideal' HbA 1c and fasting blood glucose levels at less than 7% and less than 6.6 mmol=l, respectively, 9,10 although recent epidemiological data suggest even these goals are too high.
Patients with Type 2 diabetes are treated in a step-wise manner: diet and exercise may be all that is required in the early stages of the disease to achieve acceptable glycaemic control. However, as diabetes progresses, pharmacological interventions may be required to maintain control. In the UKPDS, fewer than 20% of newly-diagnosed patients achieved specified blood glucose targets after 3 months and less than 10% were able to achieve long-term control by dietary measures alone. 11 There are a number of OHAs available that modulate different pathophysiological aspects of Type 2 diabetes mellitus, and which can be used as monotherapy or combined synergistically. Sulphonylureas are insulin secretagogues that act via specific receptors on the beta-cell surface, leading to decreased transmembrane potential and increased exocytotic activity. Metiglanides, such as repaglinide, work in a similar way, using different receptors, have a rapid onset of action and, given at meal-times, provide efficient control of postprandial glucose (PPG). They have been referred to as 'prandial glucose regulators'. Metformin acts by decreasing endogenous hepatic glucose production and increasing peripheral insulin sensitivity (as do the thiazolidenediones or 'glitazones'), while the alpha-glucosidase inhibitors delay carbohydrate absorption from the gut, an action which is shared by metformin. These drugs are primarily effective, either as monotherapy or in combination with each other, in achieving good glycaemic control for those patients in whom diet and exercise have failed. However, they have one general disadvantage: they depend upon residual beta-cell secretory capacity and when this becomes insuffient, associated with significant hypoinsulinaemia, they are no longer adequate. Eventually, OHA therapy may not be able to control blood glucose levels sufficiently to meet glycaemic targets and the patient then requires insulin in order to control escalating hyperglycaemia.
Data from the UKPDS showed that approximately 6 y after diagnosis around 50% of patients with Type 2 diabetes needed long-term insulin treatment to sustain glycaemic control. 12, 13 Patients with the lowest beta-cell function at diagnosis were at greatest risk of OHA failure (this was also true for those with the poorest baseline glycaemic control). 14 Insulin sensitivity or body mass index were not related to the onset of OHA failure, indicating that beta-cell dysfunction is the predominant flaw in the progression of Type 2 diabetes.
Insulin can be introduced simply into combination therapy
As blood glucose levels worsen in patients with OHA failure, insulin can be introduced in a step-wise fashion to restore metabolic control. However, due to the reluctance of patients and physicians to progress to insulin, regimens are often started only after oral agents have failed badly, or, more unwisely, after a prolonged period of poor control and known beta-cell failure. This reticence can be for several reasons, such as fear of complicated multiple-injection regimens, frequent blood glucose monitoring, or coping with concomitant non-diabetic medications (as discussed by Korytkowski in this publication). Nevertheless, the move to insulin therapy should not be delayed; patients with poor glycaemic control have high mortality and morbidity, low quality of life and increased healthcare costs. 15, 16 Progression to insulin therapy may be facilitated by keeping the regimens simple, while still addressing all aspects of metabolic control (including both postprandial glucose and FPG).
For Type 2 diabetic patients with some residual insulin secretion, several options are available. A dose of an intermediate or long-acting insulin may be given only once or twice daily, often best in combination with an OHA. Alternatively, a rapid-acting insulin may be administered at mealtimes, expecting the residual insulin secretion to maintain non-meal related glucose control. When insulin is started in combination with oral therapy, the eventual switch to insulin-only treatment will be easier as the patient will have already learned the practical skills needed to effectively manage their insulin regimen. Another advantage of initiating insulin therapy in combination with OHA therapy is that simple regimens can be used making it easy for the physician to adjust and titrate doses; this may also improve patient compliance. 17 Combination regimens with insulin and OHAs can be effective quite early in the course of the disease, while patients are still responsive to their OHA treatment. Intermediate-acting bedtime insulin (NPH) was added to glibenclamide alone, metformin alone, glibenclamide and metformin combined or a morning injection of NPH in a 12-month randomised controlled trial investigating different bedtime insulin regimens. 18 The most superior regimen with respect to decreases in HbA 1c , FPG, PPG and incidence of hypoglycaemia was the insulin and metformin combination (Figure 1) . In this study, and others, another advantage of insulin therapy at low doses in combination with OHAs (especially metformin) was revealed: a reduced tendency for weight gain relative to insulin monotherapy. 17, 19, 20 Insulin in combination with OHAs: better glycaemic control than OHA monotherapy Many studies and widespread clinical practice have demonstrated that in a large number of patients with OHA failure, metabolic control is significantly improved with insulin treatment (either alone or in combination with OHAs). 19,21 -30 For example, in a study of 95 patients with a mean baseline HbA 1c of 11.0%, 34 reduced their HbA 1c to below 8.0% and 25 achieved levels below 7.5% ( Figure 2) . 30 A clear decrease in fasting and mean daily glucose levels was also achieved after 6 months following the switch to insulin from OHA therapy. It has also been shown that long-term Figure 1 The combination of bedtime insulin and metformin resulted in a superior change in HbA 1c percentage points from baseline in comparison to other regimens (bedtime insulin plus metformin and glibenclamide, bedtime insulin and glibenclamide and twice daily injections of insulin). Adapted from reference 17.
The case for early insulin initiation M Marre control is better maintained in patients who have switched from OHA to insulin therapy compared to patients who remained on sulphonylureas. 21 The threat of hypoglycaemia is commonly perceived to be a risk when initiating insulin therapy. However, this mistaken belief should not prevent introduction of insulin therapy; insulin can be combined with OHAs without increasing the incidence of hypoglycaemia. It has been demonstrated that insulin combined with metformin in insulin-naïve patients has a lower risk of hypoglycaemia than insulin-only treatment, despite better glycaemic control being achieved with the combination group. 17 
Glycaemic control maintained with insulin therapy
A long-term, randomised study investigated the effects of insulin and sulphonylurea therapy on glycaemic control, insulin resistance and cardiovascular risk factors in 36 patients with Type 2 diabetes. 31 Patients were in stable glycaemic control in the 3-month run-in (two subjects on diet alone and 34 subjects on glibenclamide). They were randomly assigned to treatment with twice-daily intermediate-acting insulin (n ¼ 18) or glibenclamide (n ¼ 18). Insulin doses were adjusted by the physician or outpatient clinic to achieve pre-meal glucose levels of less than 7 mmol=l and PPG levels of less than 10 mmol=l. The insulin and glibenclamide doses were also adjusted to achieve HbA 1c levels of less than 7.5%, while avoiding hypoglycaemic events. Glycaemic control improved with insulin therapy (around half the patients receiving insulin achieved target HbA 1c levels within a year) but deteriorated with glibenclamide treatment, despite an increase in the mean dose (7.88 mg=day at baseline and 8.88 mg=day after 12 months' treatment). HbA 1c levels differed significantly between groups after 12 months of therapy (mean AE s.e.m. 7.9 AE 0.3 (insulin) vs 9.5 AE 0.4% (sulphonylurea), P ¼ 0.004) (Figure 3 ).
Experimental investigations have proposed that periods of beta-cell 'rest' can conserve, or possibly even restore, the insulin secretory ability of the pancreas. 32 -34 In one study, 32 11 patients with Type 2 diabetes were assessed twice following randomly ordered overnight infusions of somatostatin (which inhibits insulin secretion but not synthesis) and saline. Control subjects were also studied twice after overnight saline infusion. Following somatostatin treatment, the mean insulin secretion rate in the patients with Type 2 diabetes increased to rates comparable with the rate observed in controls (5.00 AE 0.83 (patients) vs 5.10 AE 0.78 (controls) pmol=kg=min, NS). Therefore, it is possible that beta-cell rest, with a consequent partial restoration of insulin secretion capacity, can be realised in patients with Type 2 diabetes by introducing insulin treatment before intractable beta-cell failure. One study has shown longer remission periods in newly diagnosed Type 2 diabetic patients initially treated with intensified insulin therapy than in those not exposed to exogenous insulin at this early stage. 35 
Improvement of patient well-being with insulin therapy
Initiating insulin treatment in patients who are poorly-controlled on OHAs may have a positive impact on their quality of life (QoL). In one study that assessed 32 patients with Type 2 diabetes, introducing insulin treatment and sustaining improved HbA 1c levels favourably affected QoL scores. 36 Thus, there are potential advantages in starting insulin early in the course of diabetes. However, there are a multitude of insulins and regimens to choose from and it is acknowledged that there is a lack of clinical data regarding the optimal combination of agents and insulins. 23 
Which insulin, which regimen?
Many patients will have been used to treating their disease for many years with OHAs alone and may be unwilling to The case for early insulin initiation M Marre begin a demanding insulin regimen. Alternatively, patients may be taking a bewildering array of oral medications for concomitant disease and again may be reluctant to start yet another treatment. Especially at present, with the tendency to delay insulin therapy, the majority of patients with Type 2 diabetes commencing insulin are likely to be elderly, so keeping insulin regimens simple is an important consideration. Traditionally, insulin therapy has usually been initiated in Type 2 diabetes as a once-or twice-daily injection of NPH. This is convenient for patients because it involves few injections, but it does not target postprandial glucose control. This may be an important clinical failing because epidemiological evidence suggests that peak levels of blood glucose after a glucose load may have a greater influence on cardiovascular outcomes than do fasting blood glucose levels (as discussed by Del Prato in this publication). 37 -41 Therefore, it may be potentially useful to choose insulin regimens that control postprandial glucose levels as well as fasting glycaemia, although a direct link between controlling post prandial glucose specifically and reduced mortality has not been shown.
Biphasic insulins are one attempt to address this need while also remaining simple to use. The use of premixed insulins may be especially recommended in the elderly, if they have trouble accurately mixing insulins for themselves. They also permit the use of pen injection devices for two types of insulin given simultaneously, obviating the need for either mixing or taking two injections. 42 Traditional biphasic insulins consist of a soluble insulin component together with longer-acting protaminated insulin, and are injected twice daily. However, one disadvantage with biphasic insulins is the recommended 30 min interval between injecting and eating; this is due to the prolonged and variable absorption of soluble insulins when injected as a depot into the subcutis. 43 
Insulin analogue premixes in combination with OHAs
Premix and dual-release formulations of the rapid-acting insulin analogues insulin aspart and insulin lispro now exist as an alternative to conventional biphasic insulins. In these, a percentage of the insulin molecules are protaminated to retard absorption, but the rapid-acting component is absorbed much faster than conventional soluble insulin, enabling the patient to employ an injection interval of 15 minutes or less before meals. The rapid absorption of the analogue component efficiently limits postprandial glucose excursions, compared to conventional biphasic insulin even if given at the 30 min preprandial time. 44 There are relatively few published data regarding the use of insulin analogue premixes and OHAs in combination, but preliminary data are encouraging. The efficacy and safety of dinnertime dual-release insulin aspart in combination with metformin was compared to dinnertime biphasic human insulin or evening NPH insulin, both combined with metformin, in a 12-week open-label, randomised, parallel-group trial. 45 The combination of metformin and dual-release insulin aspart was shown to be at least as effective as the other two regimens in terms of HbA 1c and FPG levels but with improved postprandial control after the evening meal and a reduced incidence of nocturnal hypoglycaemia. Another open-label, parallel, 16-week trial, has investigated the efficacy of dual-release insulin aspart in combination with metformin compared to dual-release insulin aspart monotherapy and to glibenclamide in combination with metformin in 136 patients with Type 2 diabetes with goodto-moderate glycaemic control (baseline HbA 1c < 9.0%) and 193 patients with poor glycaemic control (baseline HbA 1c ! 9.0%). 46 Mean HbA 1c decreases of 2.4, 2.3 and 2.0 were achieved in dual-release insulin aspart=metformin combination, dual-release insulin aspart monotherapy and glibenclamide=metformin combination, respectively. Glycaemic control improved significantly in the dual-release insulin aspart=metformin group compared to dual-release insulin aspart monotherapy (P ¼ 0.004). Patients with poor control achieved significantly better glycaemic control with dualrelease insulin aspart and metformin treatment combined compared with those on insulin monotherapy (P ¼ 0.037) or glibenclamide=metformin combination (P ¼ 0.033). There was no significant weight gain in the insulin-treated groups and no difference in the incidence of all hypoglycaemic episodes between groups. This study demonstrates that a biphasic analogue-based therapy can be added to existing OHA treatment to improve glycaemic control. It also suggests that adding insulin is more effective than adding a second OHA to the treatment regimen.
It should be noted that similar improvements in HbA 1c can be achieved by adding a bedtime injection of the novel long-acting insulin glargine to OHA regimens in Type 2 diabetes, and a direct comparison with the addition of a biphasic insulin analogue has not yet been made. 47 
Summary
In summary, the use of insulin in combination with OHAs early in the course of diabetes is a treatment option that may have several benefits, mainly: improvement of glycaemic control beyond that achieved by insulin alone; as a 'bridge' between oral-only and insulin-only therapy; possible preservation of beta-cell function; and the improvement of patient well-being. One such insulin regimen that may be employed to take advantage of these benefits, and which additionally reduces postprandial glucose exposure, is the twice-daily biphasic insulin analogues. The case for early insulin initiation M Marre
